Beta blockers in combination with class I antiarrhythmic agents

Deedwania, Prakash; Olukotun, Adeoye Y.; Kupersmith, Joel; Jenkins, Patricia C.; Golden, Patrick F.

doi:10.1016/0002-9149(87)90704-1

Cited by 19 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of class Ia and beta blockers is widely used; the most commonly reported combination is quinidine and propranolol [18,19]. However, this combination carries the possibility of QT prolongation associated with bradycardia.…”

Section: Combination Of Mexiletine With Propranololmentioning

confidence: 99%

Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias

Tanabe

1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The possibility that a magnesium deficiency might be the underlying cause of vasospastic angina (VA) and the efficacy of Mg administration in its treatment were studied. Subjects included 15 patients with VA and 18 healthy subjects as the control group. The erythrocyte Mg content was measured by atomic absorption, and serum Mg was measured by conventional chemical assay. The efficacy of Mg administration was studied in seven patients with VA. The results were as follows: a) The mean erythrocyte Mg content was less in the group with frequent episodes of angina (1.59 +/- 0.11 mg/dl) than in the group without angina (2.11 +/- 0.38 mg/dl, p less than 0.01) and in the control group (2.22 +/- 0.29 mg/dl, p less than 0.01). There was no significant difference between the control group and patients of each group with respect to serum Mg. b) Coronary arterial spasm was induced by ergonovine maleate in seven patients and was completely inhibited by the administration of Mg sulfate (40-80 mEq, hourly) in six of these patients; in the remaining patient neither obvious ST change nor chest pain occurred. Thus, it was concluded that the measurement of erythrocyte Mg content is useful to determine how easily vasospasm might occur in VA and that the administration of Mg might be developed as a new therapy for spasm associated with a low erythrocyte Mg content.

show abstract

Section: Combination Of Mexiletine With Propranololmentioning

confidence: 99%

Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias

Tanabe

1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

“…Also, ß-block¬ ers have been shown to increase ventricular fibrillation threshold in experimental animals and suppress ven¬ tricular arrhythmias in humans.22 24 Despite this welldemonstrated efficacy of ß-blockers, currently only 20% to 30% of the survivors of MI receive ß-blocker therapy for secondary prevention.28 Also, ß-block¬ ers have been shown to increase ventricular fibrillation threshold in experimental animals and suppress ven¬ tricular arrhythmias in humans.22 24 Despite this welldemonstrated efficacy of ß-blockers, currently only 20% to 30% of the survivors of MI receive ß-blocker therapy for secondary prevention.28…”

mentioning

confidence: 99%

Secondary Prevention After Myocardial Infarction

Deedwania¹

1993

Arch Intern Med

Self Cite

View full text Add to dashboard Cite

Effect of the combination of low‐dose mexiletine and metoprolol on ventricular arrhythmia

Ravid

Lampert

Graboys

1991

Clinical Cardiology

View full text Add to dashboard Cite

Summary: Antiarrhythmic drug therapy is often ineffective or poorly tolerated. Combining antiarrhythmic agents with different electrophysiologic properties may have a synergistic antiarrhythmic effect when compared with each drug alone. If a lower dose of each drug can be used, combination therapy may also result in lower incidence of side effects. 'The goal of our study was to assess the complementary effect of low-dose mexiletine and metoprolol, when compared with either drug alone. Ten patients with frequent ventricular arrhythmias including 7 patients with nonsustnined ventricular tachycardia were evaluated in an open-label sequential study. The response to drug therapy was evaluated by 24-h continuous EKG monitoring, exercise stress testing, and echocardiogram after each treatment. Combination therapy effectively reduced ventricular arrhythniias in 8 patients (80%) in contrast to only 1 patient (10%) on metoprolol alone and 4 patients (40%) on mexiletine alone. In 5 patients (7 1 %) ventricular tachycardia was abolished. The number of couplets was reduced from 51 f 3 9 to 1.9k2.4 (p

show abstract

Beta blockers in combination with class I antiarrhythmic agents

Cited by 19 publications

References 22 publications

Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias

Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias

Secondary Prevention After Myocardial Infarction

Effect of the combination of low‐dose mexiletine and metoprolol on ventricular arrhythmia

Contact Info

Product

Resources

About